The reiteration of an Overweight rating and the maintenance of a $45 price target by a reputable analyst like Kristen Kluska from Cantor Fitzgerald could positively influence investor sentiment towards PTC Therapeutics. This endorsement reaffirms the analyst's confidence in the company's prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.